Project cooperationUpdated on 19 January 2026
Translational Research Platform based on human tissues and primary cells
Chief Executive Officer at Humana Biosciences
31670 - LABEGE, France
About
Humana Biosciences is a Preclinical Contract Research Organization based in France. We are focused on translational research assays. The company offers preclinical research services to Pharma, biotech & nutraceutical companies, as well as Academic Laboratories based in Europe and developing novel drugs or nutritional solutions in the following therapeutic areas: Dermatology, Gastro-Intestinal, Respiratory, Urology and Gynecology.
What We Offer to Horizon Europe Consortia
1. New Approach Methodologies (NAMs) / Alternative to Animal Testing
-
Validated technologies and assays to generate human-relevant, functional cellular readouts, like:
-
Human tissues obtained from European Hospitals (fresh, frozen and paraffin-embedded) from healthy controls as well as selected patients
-
Human primary cells in 3D cultures
-
Human isolated organs for smooth muscle contractility studies and neurotransmitters release
2. Advanced Tools for testing chemicals and drug candidates
-
Large experience in testing small molecules, peptides, plant extracts and Advanced Therapy Medicinal Products.
-
Real-time monitoring of tumor cell lines or human primary epithelial cells and immune cells isolated from healthy individuals or patients to evaluate cell viability, proliferation and growth inhibition.
-
Real-Time Cell Metabolic Analysis, providing a clear window into the critical functions driving cell signaling, proliferation, activation, toxicity and biosynthesis.
3. Regulatory Science & Translational Development
-
Expertise in designing robust analytical assays for drug discovery and safety assessment.
-
Strong alignment with calls requiring quantitative, reproducible, patient-relevant data.
What we are looking for (ideal consortium fit):
We are interested in joining consortia that aim to develop or validate NAM platforms (e.g., human primary cells in 3D cultures, human tissue-relevant assays, pharmacological characterization of receptors in functional assays on human isolated tissues, as well as imaging readouts, requested by our partners to characterize and validate new drug candidates.
Topic
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
Type
- Partner seeks Consortium/Coordinator
Organisation
Similar opportunities
Project cooperation
iPSC-derived neuronal models in 2D and 3D
- Partner seeks Consortium/Coordinator
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
Dáša Bohačiaková
PI at Masaryk University
Brno, Czech Republic
Project cooperation
Translational NAMs in pharmacology & toxicology for drug profiling
- Partner seeks Consortium/Coordinator
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
Nikolas Dietis
Assistant Professor of Pharmacology at University of Cyprus
Nicosia, Cyprus
Project cooperation
- Partner seeks Consortium/Coordinator
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
Mark Davison
Research and Innovation Projects Coordinator - EC at Technion Israel Institute of Technology
Haifa, Israel